Abstract

PostScription: It Is Not Just What You Say…But How You Say It!

Author(s): Reed-Kane Dana

Issue: Jul/Aug 2008 - Hormone Replacement Therapy

View All Articles in Issue

Page(s): 375

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2008 Pg. 375	PostScription: It Is Not Just What You Say…But How You Say It! Author(s): Reed-Kane Dana
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Mar/Apr 2010 Pg. 165-170	Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study Author(s): Moro Doris, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Jul/Aug 2004 Pg. 313-319	Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
May/Jun 2006 Pg. 175-183	The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Mar/Apr 2008 Pg. 122-127	Hormone Therapy: It's Time for a Second Opinion Author(s): Collins Joseph J, Ahlgrimm Maria
Jul/Aug 2007 Pg. 326-327	Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Author(s): Kupiec Tom, Kemp Jesse
Sep/Oct 2016 Pg. 359-364	Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Author(s): Deleruyelle Laura J
Jul/Aug 2005 Pg. 266	Guidelines for Consulting with Patients about Bioidentical Hormone Replacement Therapy Author(s): White Irene Q
Jan/Feb 2002 Pg. 50-54	Bioidentical Hormone Replacement Therapy, Part 2, A Review of Author(s): Wepfer Scott T
Jul/Aug 2007 Pg. 350-351	PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Author(s): Allen Loyd V Jr